Skip to Content
Merck
CN

SML1599

VR23

≥98% (HPLC)

Synonym(s):

7-Chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline, 7-Chloro-4-[4-[(2,4-dinitrophenyl)sulfonyl]-1-piperazinyl]-quinoline, VR-23

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C19H16ClN5O6S
CAS Number:
1624602-30-7
Molecular Weight:
477.88
UNSPSC Code:
12352200
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

VR23, ≥98% (HPLC)

SMILES string

[S](=O)(=O)(N2CCN(CC2)c3c4c(ncc3)cc(cc4)Cl)c1c(cc(cc1)[N+](=O)[O-])[N+](=O)[O-]

InChI key

PDQVZPPIHADUOO-UHFFFAOYSA-N

InChI

1S/C19H16ClN5O6S/c20-13-1-3-15-16(11-13)21-6-5-17(15)22-7-9-23(10-8-22)32(30,31)19-4-2-14(24(26)27)12-18(19)25(28)29/h1-6,11-12H,7-10H2

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Related Categories

Biochem/physiol Actions

Potent inhibitor of proteasome that primary targets β2 of the 20S proteasome catalytic subunit
Proteasomes are responsible for the cleavage of peptides in an ATP/ubiquitin-dependent manner.
VR23 is a potent inhibitor of proteasome that primary targets β2 of the 20S proteasome catalytic subunit. VR23 selectively induces apoptosis to cancer cells via cyclin E–mediated centrosome amplification. VR23 exhibit little effect on noncancerous cells.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
046M4619V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sheetal Pundir et al.
Cancer research, 75(19), 4164-4175 (2015-08-05)
The proteasome is clinically validated as a target for cancer therapeutics. However, proteasome-inhibitory agents that are cancer selective have yet to be developed. In this study, we report the identification of a safe and effective proteasome inhibitor with selective anticancer
G Munkácsy et al.
British journal of cancer, 102(2), 361-368 (2009-12-17)
To date individual markers have failed to correctly predict resistance against anticancer agents in breast cancer. We used gene expression patterns attributable to chemotherapy-resistant cells to detect potential new biomarkers related to anthracycline resistance. One of the genes, PSMB7, was

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service